NeurAxis (NRXS) Q4 2025: Prior Auth Submissions Surge 10x as CPT Code Unlocks Pediatric Pipeline
NeurAxis enters 2026 with a transformed growth profile, propelled by a 10x surge in prior authorization submissions and expanded payer coverage following the Category 1 CPT code for IB STEM. The company’s commercial focus now shifts from access-building to execution, as pediatric adoption accelerates and groundwork is laid for adult and VA expansion. Investors should watch for continued payer wins and operational scaling as key catalysts for multi-year growth.
Summary
- Payer Coverage Expansion: Category 1 CPT code and 100M covered lives drive real-world adoption inflection.
- Operational Scaling: Commercial hiring and targeted hospital engagement underpin a shift to execution focus.
- Adult and VA Pathways: Strategic trials and VA rollouts lay the foundation for future addressable market expansion.
Performance Analysis
NeurAxis delivered its sixth consecutive quarter of double-digit revenue growth, reflecting successful commercial execution and payer traction for its PENFS and IB STEM neuromodulation devices. Q4 revenue growth was underpinned by a 35% YoY increase in unit deliveries, with a marked shift toward higher-margin, fully reimbursed patients as major insurer coverage took effect. This mix shift, enabled by the new Category 1 CPT code, is expected to continue fueling top-line momentum into 2026.
Gross margin dipped slightly due to inventory reserves and the lower-margin RED device, but management expects margin recovery as discounted sales transition to reimbursed revenue. Operating expenses rose 20% YoY, driven by increased sales commissions, marketing, and targeted hiring ahead of broader commercial rollout. The net loss widened modestly, but cash flow remains manageable with a $6M+ cash balance and additional ATM facility capacity. Importantly, the company’s financial leverage is expected to improve as revenue scales faster than opex growth, supporting a sustainable runway for commercial expansion.
- Mix Shift to Reimbursed Revenue: Q4 saw a material increase in high-margin, fully insured patient sales, reducing reliance on discounted programs.
- Expense Investment for Growth: Selling and R&D spend rose to support commercial hiring and device enhancement, while G&A is held flat for leverage.
- Cash Position Stable: Over $6M in cash post-quarter, with additional ATM capacity and prudent expense management supporting growth plans.
The quarter marks a clear transition from access-building to execution, with payer wins and operational scaling setting the stage for accelerated adoption and margin recovery in 2026.
Executive Commentary
"For the first time, the story has become significantly easier to understand. With a Category 1 CPT code in place and more than 100 million covered lives, our focus has shifted from access creation to execution, identifying what remains missing and closing those gaps to unlock maximum growth."
Brian Carrico, Chief Executive Officer
"Revenues in the fourth quarter of 2025 were $968,000, up 27% compared to $761,000 in the fourth quarter of 2024. Unit deliveries increased 35% compared to the prior year due to volume growth from patients with full reimbursement health insurance... we expect a positive mixed shift impact on revenue will continue into the first quarter."
Tim Hendricks, Chief Financial Officer
Strategic Positioning
1. Pediatric Market Focus with Payer-Driven Adoption
NeurAxis’ core business model is built around neuromodulation for pediatric gastrointestinal disorders, with IB STEM as the flagship device. The Category 1 CPT code and expanded written insurance policy coverage have unlocked a new phase of adoption, but management stresses that written policy coverage, not just the CPT code, is essential for broad access. The company’s internal prior auth team is scaling to help hospitals navigate reimbursement and drive more consistent patient access.
2. Commercial Execution and Hospital Enablement
Execution focus has shifted to scaling commercial infrastructure, including hiring medical science liaisons, market development specialists, digital marketing, and sales reps. The team is engaging directly with children’s hospitals, prioritizing those with high utilization potential and providing financial modeling to hospital administrators. Only a small fraction of hospitals are currently at capacity, revealing significant untapped upside as operational bottlenecks are addressed.
3. Adult and VA Market Expansion
While pediatric adoption remains the near-term growth engine, NeurAxis is laying groundwork for adult and VA market entry. A randomized controlled trial with Cleveland Clinic aims to generate the data needed for adult payer coverage, while the new VA FSS contract opens access to a large federal population. Early VA facility orders and positive feedback suggest incremental upside, with a national sales force model under consideration for future scale.
4. Pipeline Indications and Data-Driven Advocacy
The company is investing in studies for new indications, including cyclic vomiting syndrome and post-op pain, with readouts expected over the next 18 months. Advocacy efforts highlight the clinical need for non-drug options, leveraging published guidelines and expert opinion to influence payer policy and hospital adoption.
Key Considerations
This quarter marks a strategic inflection point as NeurAxis pivots from building access to driving utilization and operational scale. The business model, built on device-based reimbursement, now benefits from structural tailwinds as payer coverage and CPT coding converge.
Key Considerations:
- Payer Policy as Growth Gatekeeper: Written insurance policy coverage, not just CPT code, is essential for real-world adoption and remains the top commercial priority.
- Hospital Operational Bottlenecks: Most children’s hospitals are not yet treating at capacity due to clinic time, committee processes, and partial payer coverage, creating a multi-quarter ramp opportunity.
- Commercial Team Scale-Up: Aggressive hiring across sales, medical affairs, and marketing will be key to unlocking hospital and VA penetration.
- Adult Market Requires Evidence: Payer coverage for adults will depend on successful completion of the Cleveland Clinic trial, with a timeline of 18 months or more.
- Margin Recovery Path: As discounted sales convert to reimbursed revenue, gross margin is expected to rebound, supporting operating leverage and cash flow improvement.
Risks
Primary risks center on the pace and breadth of payer policy adoption, as well as hospital operational inertia that could slow patient ramp. Delays in the adult trial or VA rollout could push out future revenue streams. Competitive device or drug entrants, reimbursement changes, or regulatory shifts could also pressure growth and margins. Management’s ability to execute a national commercial rollout with disciplined expense control will be critical as the company scales.
Forward Outlook
For Q1 2026, NeurAxis signaled:
- Significantly higher prior authorization submission rates, up nearly 10x YoY, with revenue “better than expected.”
- Continued commercial hiring and hospital engagement to drive utilization ramp.
For full-year 2026, management did not provide formal guidance but emphasized:
- Ongoing expansion in payer policy coverage as the key growth lever.
- Margin recovery as mix shifts to reimbursed sales and opex grows slower than revenue.
Management highlighted several factors that will shape the year:
- Payer negotiations and policy reviews scheduled through H1 2026.
- Data-driven commercial execution focused on hospital enablement and operational scaling.
Takeaways
NeurAxis’ Q4 and early 2026 results confirm a structural inflection, with payer coverage and operational execution now the main levers for growth and margin expansion.
- Payer-Driven Adoption: The 10x increase in prior auth submissions and 100M covered lives signal a new phase of scalable growth, but full coverage is needed for universal hospital adoption.
- Execution-Heavy Ramp: Commercial hiring, hospital enablement, and operational bottleneck resolution will determine the slope of adoption and margin recovery in 2026.
- Pipeline Optionality: Adult and VA markets, as well as new indications, provide long-term upside but are contingent on clinical data and payer policy wins.
Conclusion
NeurAxis has crossed a pivotal threshold, with payer coverage and CPT coding unlocking real-world adoption and a multi-year growth runway. Execution on commercial scaling and policy expansion will be the critical variables as the company seeks to capture its addressable market and drive margin leverage.
Industry Read-Through
NeurAxis’ trajectory underscores the critical importance of payer policy and CPT coding for device-based therapeutics, especially in pediatric and specialty markets. The experience highlights that written insurance coverage, not just coding, is the true gatekeeper for adoption, a lesson for peers in neuromodulation, diagnostics, and digital health. The operational bottlenecks faced by hospitals—clinic time, committee approvals, and reimbursement uncertainty—are likely to impact other novel therapies seeking broad institutional adoption. For medtech investors, the NRXS story signals that commercial execution and payer advocacy are as important as clinical data in driving inflection and value creation.